Christopher Bi
About Christopher Bi
Christopher Bi is the Executive Director of Integrative Sciences at Bristol Myers Squibb in San Diego, California, and serves as a Board Observer at Nitrase Therapeutics and a Member of the Board of Directors at The Structural Genomics Consortium (SGC). He has nearly two decades of experience in integrative sciences and external research solutions, having held multiple senior roles at Pfizer.
Current Role at Bristol Myers Squibb
Christopher Bi serves as the Executive Director, Integrative Sciences at Bristol Myers Squibb located in San Diego, California. His role encompasses overseeing initiatives that integrate various scientific disciplines to drive pharmaceutical advancements. His leadership focuses on the development and implementation of integrative scientific strategies to enhance drug discovery and development.
Professional Involvement at Nitrase Therapeutics
In addition to his role at Bristol Myers Squibb, Christopher Bi is a Board Observer at Nitrase Therapeutics. In this strategic position, he provides valuable insights and guidance, helping to shape the company's direction in the biotechnology landscape. His expertise in integrative sciences and extensive industry experience contribute to Nitrase Therapeutics' ongoing growth and innovation.
Membership on The Structural Genomics Consortium (SGC) Board
Christopher Bi actively contributes to the scientific community through his role as a Member of the Board of Directors at The Structural Genomics Consortium (SGC). The organization focuses on the discovery of novel proteins and their structures, facilitating advancements in drug discovery. His participation underscores his commitment to fostering collaborative research and development in structural genomics.
Career at Pfizer
Christopher Bi had a notable career at Pfizer, ranging from 2004 to 2020. His roles included Senior Scientist, Principal Scientist, Senior Principal Scientist, Research Project Leader in Oncology Research and Development, and Director of External Research Solutions. He contributed consistently to various research projects, particularly focusing on integrating external research solutions and advancements in oncology. His work in La Jolla Laboratories significantly impacted Pfizer's research and development efforts.
Educational Background
Christopher Bi holds a PhD in Synthetic Organic Chemistry from Stanford University, which he completed in 2003. He furthered his education with an Executive MBA from the University of California, San Diego - Rady School of Management, completed in 2012. His academic background laid a strong foundation for his career in integrative sciences and research leadership within the pharmaceutical industry.